Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of QRL-101 Formulations in Healthy Participants
NCT06877624Phase 1Completed
- Sponsor
- QurAlis
- Start
- Jan 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of QRL-101 in amyotrophic lateral sclerosis (ALS) and epilepsy (6 arms), sponsored by QurAlis. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and 3 more. Started Jan 2025; status: completed.
02
Drugs
QRL-101
03
Conditions
amyotrophic lateral sclerosis (ALS)epilepsy
Beyond the preview
Go deeper on NCT06877624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06877624.